Ubs Group Ag Bio N Tech Se Call Options Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $2.93 Million - $4.66 Million	37,400 Added 69.13%	91,500 $10.9 Million
Q2 2024 Aug 13, 2024	SELL	$80.36 - $102.87 $38.1 Million - $48.8 Million	-474,200 Reduced 89.76%	54,100 $4.35 Million
Q1 2024 May 13, 2024	BUY	$88.96 - $112.35 $34.7 Million - $43.9 Million	390,300 Added 282.83%	528,300 $48.7 Million
Q4 2023 Feb 09, 2024	BUY	$90.91 - $112.75 $1.55 Million - $1.92 Million	17,000 Added 14.05%	138,000 $14.6 Million
Q3 2023 Nov 09, 2023	BUY	$98.5 - $125.08 $11.9 Million - $15.1 Million	121,000 New	121,000 $13.1 Million
Q1 2023 May 12, 2023	SELL	$122.57 - $153.67 $1.97 Million - $2.47 Million	-16,100 Reduced 39.17%	25,000 $3.11 Million
Q4 2022 Feb 08, 2023	BUY	$118.43 - $186.05 $4.87 Million - $7.65 Million	41,100 New	41,100 $6.17 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $12.1 Million - $22.2 Million	-95,900 Reduced 95.9%	4,100 $699,000
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $64,991 - $108,756	-300 Reduced 0.3%	100,000 $25.8 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $61,779 - $134,169	300 Added 0.3%	100,300 $27.4 Million
Q1 2021 May 12, 2021	BUY	$85.73 - $119.5 $8.57 Million - $12 Million	100,000 New	100,000 $10.9 Million

356

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.